Articles tagged with Opportunistic Infections
Researchers at Johns Hopkins School of Public Health discovered that administering itraconazole to HIV-positive patients with P. Marneffei infection can prevent relapse, reducing the risk by 100%. The study showed a 50% relapse rate among untreated patients compared to zero in those treated with itraconazole.
Jay A. Levy, a UCSF professor of medicine, suggests delaying antiviral therapy for HIV infection until the CD-4 cell count falls below 400 and the viral load is above 30,000 copies per milliliter. This approach aims to avoid drug resistance and allow the immune system to recover and control the virus.
Researchers at UCSF found that patients with HIV who undergo aggressive therapy have a robust response to cytomegalovirus, which causes blindness in people with AIDS. This suggests that CD4+ T cells replenished by therapy can mount effective responses against specific pathogens.
Researchers at NIAID have found that the virus rapidly rebounds to high levels when drugs are discontinued due to normal stimulatory factors present in the environment of a patient's lymph nodes. The new data suggest that these factors can activate HIV hidden in immune system cells, leading to their death and further viral spread.